Bellerophon Therapeutics (BLPH) Tops Q3 EPS by 6c

Bellerophon Therapeutics (NASDAQ: BLPH) reported Q3 EPS of ($0.53), $0.06 better than the analyst estimate of ($0.59).

For earnings history and earnings-related data on Bellerophon Therapeutics (BLPH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'